COMPANY

KaliVir Immunotherapeutics

HQ: Pittsburgh, PA source · kalivir.com ↗ · Mid-Atlantic

Keywords: oncology cancer Microsatellite Stable Colorectal Cancer Head and Neck Squamous Cell Carcinoma Cervical Cancer Kidney Cancer Renal Cell Carcinoma Melanoma Stage IV Merkel Cell Carcinoma of Skin Mesothelioma Non-small Cell Lung Cancer Cutaneous Squamous Cell Carcinoma Urothelial Carcinoma Bladder Squamous Cell Carcinoma

Location: Pittsburgh, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)1NIH grants

Funding and NIH signals

NIH award NIH awarded $307K (SBIR Phase II 1R44CA314562-01, new, notice Sep 3, 2026). NIH RePORTER 1R44CA314562-01 (Sep 3, 2026)
Evidence (1 event)
- Sep 3, 2026 · NIH RePORTER 1R44CA314562-01
  Organization: KALIVIR IMMUNOTHERAPEUTICS, INC; City/State: PITTSBURGH, PA; Project number: 1R44CA314562-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 306756; Administering IC: National Cancer Institute; Project title: Translation of the novel oncolytic immunotherapy VET6-PDI; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 16, 2024 Trial start Phase 1: A Study of VET3-TGI in Patients With Solid Tumors source ↗

Upcoming milestones

Sep 30, 2027 (ESTIMATED) · Phase 1 · A Study of VET3-TGI in Patients With Solid Tumors · NCT06444815

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06444815	A Study of VET3-TGI in Patients With Solid Tumors	Phase 1	Recruiting	Sep 16, 2024	Sep 30, 2027 (estimated)

NIH awards 1

Annual award amounts. Total $307K.

Sep 3, 2026 NIH award 1R44CA314562-01 FY2026: $306,756 awarded for that fiscal year; activity R44 (SBIR); PI THORNE, STEPHEN H; recipient as written: KALIVIR IMMUNOTHERAPEUTICS, INC, PITTSBURGH, PA. Translation of the novel onco source ↗